Genetically Engineered Mosquitoes
Proposed for Release in California: Risks and Concerns

California is poised to be the second state where genetically engineered (GE) mosquitoes are released, unless the public and California’s government officials demand otherwise. Earlier this year, half a billion GE mosquitoes were released in Florida. Now, 12 California counties are targeted for the largest mass releases of GE mosquitoes (potentially including Alameda, Riverside, Fresno, Tulare, Stanislaus, Los Angeles, Orange, Sacramento, Yolo, Shasta and San Bernardino). This open-air genetic experiment poses significant environmental and public health risks.

Summary of Concerns
Oxitec, a UK-based corporation, is proposing a mass release in California even though:

• No endangered species assessments have been done;
• No assessment of potential human health impacts have been done;
• This could result in hybrid mosquitoes that may be more aggressive, more difficult to eradicate, and may increase the spread of mosquito-borne disease;
• The communities where the GE mosquitoes would be released have not been consulted and have not consented to being part of this open-air genetic experiment; and
• Oxitec claims the data and results from earlier trials in other countries and in Florida are confidential business information and will not make them available to the public.

What is the GE Mosquito?
Oxitec has genetically engineered *Aedes aegypti* mosquitoes to depend on the presence of tetracycline, an antibiotic, and to die in its absence. In theory, the GE male mosquitoes would mate and their tetracycline-dependent gene would be passed on to their offspring. The offspring are meant to die in the late larval or pupal stage. The proposed experiment is meant to determine whether the mass release of GE mosquitoes can reduce the population of *Aedes aegypti*, one mosquito species that can carry the viruses that cause yellow fever, dengue, chikungunya and Zika.1 None of these diseases are endemic in California or in the U.S. outside of Puerto Rico.2 While limiting the spread of mosquito-borne disease is important, once GE mosquitoes are released into the wild, there is no calling them back, and scientists have raised important concerns about the efficacy and potential risks associated with this open-air experiment.
Scientific Concerns

To date, GE mosquito trials have failed to reduce mosquito populations. Oxitec has conducted GE mosquito field trials in the Cayman Islands, Malaysia, Panama and Brazil. To date, none have effectively reduced the *Aedes aegypti* mosquito population.\(^3\) Also to date, there is no publicly available data from the 2021 field trials in Florida, neither from Oxitec nor the Monroe County (Florida Keys) mosquito control district, to support Oxitec’s claims that their GE mosquitoes reduced local *Aedes aegypti* populations.

Hybrid GE-wild mosquitoes could be created that may be more resistant to pesticides and more aggressive. Data from a trial in Brazil found genetic material from Oxitec’s GE mosquitoes in wild mosquitoes, creating hybrid mosquitoes.\(^4\) The researchers concluded that hybrid wild-GE mosquitoes could result in increased mosquito populations and could potentially contribute to the spread of viral diseases like Zika, West Nile, and Dengue.\(^5\) A study highlighted that these hybrid mosquitoes may be more resistant to insecticides and even more aggressive than their wild counterparts. Wild hybrids may also be able to transmit viruses more easily.\(^6\)

Reduction in populations of one type of mosquito could result in an increase in others. *Aedes aegypti* mosquitoes are only one of several species of mosquitoes that can carry diseases. If the experiment succeeded in reducing populations of *Aedes aegypti*, other varieties, such as the *Aedes albopictus* (Asian tiger), which also transmit dengue and other similar viruses, could increase in number to fill the ecological niche.\(^7,8\)

Female GE mosquitoes could survive and spread disease. Oxitec’s trial application states that female offspring — which bite and spread disease — will die before they mature into adults, and therefore exposure to biting female mosquitoes is not anticipated. However, females have been inadvertently released in Oxitec’s experiments.\(^9,10\) Data also show that females may survive in the presence of tetracycline — an antibiotic that is widely used in California agriculture and therefore present in the environment. Because of the very large numbers of GE mosquitoes proposed for release (up to 30,000 mosquitoes per acre, per week), even a small percentage of surviving biting female GE mosquitoes may lead to a significant number of females in the environment. This could lead to an increased mosquito population in the nearly 100,000 acres in California where mosquitoes are proposed for release.

GE mosquitoes may inject novel proteins into humans and other animals. Biting female GE mosquitoes may inject a novel engineered protein into humans and other animals.\(^11\) Oxitec has yet to show that these novel proteins would not harm humans or other animals. However, EPA declares that the risk assessment information about allergenic or toxic effects of the genes inserted into the mosquitoes is “confidential.”\(^12,13\)
No studies have been completed to assess risks to endangered species. There are 87 federally listed endangered species in the state of California. Yet, the U.S. Environmental Protection Agency (EPA) has not required any endangered species assessments prior to the release of GE mosquitoes. Feeding trials for key mammals and birds could provide important insights about what impacts the GE mosquitoes may have on endangered or threatened species. However, no feeding trials have been done for mammals or birds, only for “aquatic invertebrates” (crayfish and guppies).

Lack of Transparency

Oxitec’s proposal has not undergone independent scientific review, and EPA has not convened a Scientific Review Panel as it has done for other new pesticides. Neither the full proposal nor data from the 2021 releases in Florida are publicly available. In addition, Oxitec’s community engagement has not been transparent. In 2021, Oxitec released GE mosquitoes as part of an experimental trial in Monroe County, Florida. Neither the mosquito control board nor Oxitec informed community residents about the locations of release until three days beforehand. Residents were not given advance warning about the exact date the release was set to occur and there was no free and prior informed consent by affected community members — a fundamental tenet of any research involving human subjects.

Lack of Regulations Specific to GE Insects

Currently, there are no regulations in the U.S. specific to GE insects. EPA regulates GE mosquitoes as biopesticides under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), but because of their potential impacts on the environment and human health, critics have named the need for full environmental and health assessment and oversight. Prior to any further consideration of a release in California, CEQA analysis, as well as regulations specific to GE insects, must be in place. In addition, government agencies must not solely rely upon company self-assessment of risks and must require third-party peer-reviewed public health and environmental assessments.

For More Information: Contact Dana Perls, Food and Technology Program Manager, Friends of the Earth, Dperls@foe.org or see https://foe.org/projects/gmo-animals/
Endnotes


5 Ibid

6 Ibid


12 Kofler, N., Kuzma, J. (2020) Before genetically modified mosquitoes are released, we need a better EPA. https://www.bostonglobe.com/2020/06/22/opinion/ before-genetically-modified-mosquitoes-are-released-we-need-better-epa/.


17 Kofler, N., Kuzma, J. (2020) Before genetically modified mosquitoes are released, we need a better EPA. https://www.bostonglobe.com/2020/06/22/opinion/before-genetically-modified-mosquitoes-are-released-we-need-better-epa/.